BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11338792)

  • 1. [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
    Scheen AJ
    Rev Med Liege; 2001 Mar; 56(3):186-9. PubMed ID: 11338792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopidogrel: a review of its use in the prevention of atherothrombosis.
    Jarvis B; Simpson K
    Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
    CAPRIE Steering Committee
    Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clopidogrel and [symbol: see text] ticlopidine--improvements on aspirin?
    Drug Ther Bull; 1999 Aug; 37(8):59-61. PubMed ID: 10696686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
    Montalescot G
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
    Tran H; Anand SS
    JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
    Hacke W
    Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy.
    Hiatt WR
    J Intern Med; 2002 Mar; 251(3):193-206. PubMed ID: 11886478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy in populations at high risk of atherothrombosis.
    Faxon DP; Nesto RW
    J Natl Med Assoc; 2006 May; 98(5):711-21. PubMed ID: 16749646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
    Zusman RM; Chesebro JH; Comerota A; Hartmann JR; Massin EK; Raps E; Wolf PA
    Clin Cardiol; 1999 Sep; 22(9):559-73. PubMed ID: 10486695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
    Bhatt DL; Topol EJ;
    Am Heart J; 2004 Aug; 148(2):263-8. PubMed ID: 15308995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel for cerebrovascular prevention.
    Paciaroni M; Bogousslavsky J
    Cerebrovasc Dis; 1999; 9(5):253-60. PubMed ID: 10473907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
    Aronow WS
    Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence with antiplatelet therapy and ADP-receptor antagonists.
    Easton JD
    Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
    Sudlow CL; Mason G; Maurice JB; Wedderburn CJ; Hankey GJ
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD001246. PubMed ID: 19821273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
    Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clopidogrel and acute coronary syndrome.
    Drug Ther Bull; 2002 Jun; 40(6):41-2. PubMed ID: 12143264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thienopyridines in coronary artery disease.
    Berger PB
    Curr Cardiol Rep; 1999 Sep; 1(3):192-8. PubMed ID: 10980841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.